Market brief
Cell & Gene Therapy Europe 2026: CAR-T, Stem Cell, ATMP, Regenerative
European cell and gene therapy (CGT) in 2026 spans clinical-stage therapeutics developers, viral-vector CDMOs, tools and platforms, and adjacent tissue-engineering and regenerative-medicine operators. The directory surfaces 26 CGT-adjacent operators. Germany concentrates therapeutics innovators (T-Knife TCR-T Berlin, RHEACELL stromal cell Heidelberg, TolerogenixX tolerogenic dendritic cell Heidelberg) plus Miltenyi Biotec (Bergisch Gladbach) as the European cell-therapy tools + clinical-manufacturing anchor and IDT Biologika (Dessau-Rosslau) as the viral-vector + fill-finish CDMO. Sweden holds Anocca (TCR-T), Elicera (CAR-T + oncolytic viruses), Verigraft (tissue-engineered vascular grafts), and Xintela (stem-cell ATMP). Norway has Zelluna (TCR-NK) and ClexBio (hydrogel scaffolds). Denmark adds Fuse Vectors (platform-stage cell-free AAV). Poland hosts PolTREG (T-reg cells, Gdansk) and Bioceltix (veterinary cell therapy, Wroclaw). Switzerland has Cimeio (shielded-cell + gene editing, Basel) and Antion Biosciences (allogeneic CAR-T + multiplex gene silencing, Geneva). Finland holds the Kuopio Center for Gene and Cell Therapy (AAV + adenovirus + lentivirus CDMO), FinVector (clinical-to-commercial viral vector), 3PBIOVIAN, StemSight (iPSC corneal ATMP, Tampere), and Rokote Laboratories. The Baltic layer adds Stem Cell Research Center and Froceth (adipose cell therapy) in Vilnius plus PrintyMed biomaterials in Latvia. The Viral Vector CDMO Europe 2026 brief covers the CDMO layer in depth.
Summary
Key findings
CAR-T, TCR-T, and CAR-NK therapeutics cluster across Germany (T-Knife Berlin), Sweden (Anocca Södertälje, Elicera Gothenburg), Norway (Zelluna Oslo), and Switzerland (Antion Geneva, Cimeio Basel) — 6 operators running clinical-stage engineered immune-cell programmes.
Regenerative medicine + stem-cell ATMPs: RHEACELL (Heidelberg), Xintela (Lund), StemSight (Tampere iPSC-corneal), Verigraft (Gothenburg tissue-engineered vascular grafts), ClexBio (Oslo hydrogel scaffolds), plus Stem Cell Research Center Vilnius and PrintyMed Latvia biomaterial scaffolds.
Regulatory T-cell and tolerance-based cell therapy: PolTREG (Gdansk, Type 1 diabetes + multiple sclerosis) and TolerogenixX (Heidelberg, tolerogenic dendritic cells for autoimmune + transplant medicine).
The viral-vector CDMO backbone for European CGT runs through FinVector (Kuopio, clinical-to-commercial), Kuopio Center for Gene and Cell Therapy (AAV + adeno + lenti), 3PBIOVIAN (Turku), IDT Biologika (Dessau-Rosslau), Fuse Vectors (Copenhagen, platform-stage cell-free AAV) — see the Viral Vector CDMO Europe 2026 brief for the detailed map.
Numbers
Quick numbers
Analysis
Engineered immune-cell therapy: CAR-T, TCR-T, CAR-NK
Engineered immune-cell therapy is the most commercially active CGT vertical in 2026. The European directory surfaces six operators at clinical stage. T-Knife (Berlin) runs TCR-T cell therapy for solid tumors. Anocca (Södertälje, Sweden) develops TCR-T cellular immunotherapy with in-house manufacturing and engineered-immunity platforms. Elicera Therapeutics (Gothenburg) combines CAR-T, oncolytic viruses, and immuno-oncology cell-therapy pipelines. Zelluna ASA (Oslo) runs off-the-shelf TCR-NK cell therapy for solid-tumour oncology, with MAGE-A4 as its lead programme. Antion Biosciences (Geneva) develops allogeneic CAR-T with multiplex miRNA gene silencing as its engineering platform. Cimeio Therapeutics (Basel) runs shielded-cell + immunotherapy pairs for hematologic disorders using gene editing. For sponsors evaluating European CAR-T / TCR-T / CAR-NK partners, these six operators are the directory-visible clinical-stage layer.
Analysis
Stem-cell therapy, regenerative medicine, tissue engineering
Stem-cell and regenerative-medicine ATMPs form the second major European CGT track. RHEACELL (Heidelberg) runs stromal-cell therapy and advanced therapeutics at clinical development stage. Xintela (Lund, Sweden) combines stem-cell therapy, ATMP manufacturing, regenerative medicine, and targeted oncology. StemSight (Tampere, Finland) develops iPSC-derived corneal cell therapy for limbal stem cell deficiency. Verigraft (Gothenburg) develops tissue-engineered vascular grafts as ATMPs. ClexBio (Oslo) operates hydrogel scaffold technology for tissue engineering. PrintyMed (Jelgava District, Latvia) manufactures biomimetic spider-silk biomaterial scaffolds and organ-on-a-chip membranes. Vital3D (Vilnius) runs 3D bioprinting + vascularized tissue models. Stem Cell Research Center Vilnius operates academic-research + regenerative-medicine cluster infrastructure. Froceth (Vilnius) runs adipose-derived cell therapy for individualised cancer immunotherapy. Together, these nine operators form the European regenerative / stem-cell ATMP + tissue-engineering layer the directory surfaces.
Analysis
Tolerance-based and T-regulatory cell therapy
Tolerance induction is a distinct CGT sub-modality with two directory operators. PolTREG (Gdansk, Poland) develops T-regulatory cell therapy for Type 1 diabetes and multiple sclerosis at clinical stage — one of the few European T-reg programmes the directory surfaces at this scope. TolerogenixX (Heidelberg, Germany) develops tolerogenic dendritic cell therapy for autoimmune disease and transplant medicine. Both operators target immune-tolerance endpoints rather than immune-activation (CAR-T / TCR-T) endpoints. For sponsors building European CGT partnerships in autoimmune or transplant medicine, these are the two directory entries with disclosed clinical-stage tolerance-based programmes.
Analysis
Veterinary cell therapy
Veterinary CGT is a niche but commercially active sub-modality. Bioceltix (Wroclaw, Poland) operates veterinary cell-therapy manufacturing for animal-health applications with allogeneic stem-cell products at commercial scope — the directory entry with the most visible European veterinary-CGT operating record. For sponsors partnering in veterinary therapeutics, Bioceltix is the directory’s default Polish-innovation-belt entry point.
Analysis
The viral-vector and tools supply chain
European CGT supply depends on viral-vector manufacturing and a specialised tools layer. The viral-vector CDMO backbone runs through FinVector (Kuopio, clinical-to-commercial AAV + adenoviral), the Kuopio Center for Gene and Cell Therapy (GMP AAV + adenovirus + lentivirus), 3PBIOVIAN (Turku, biologics + viral vectors + pDNA), IDT Biologika (Dessau-Rosslau, viral vector + vaccine + fill-finish at commercial scale), and Fuse Vectors (Copenhagen, platform-stage cell-free AAV manufacturing). On the tools + clinical-manufacturing side, Miltenyi Biotec (Bergisch Gladbach, Germany) operates cell-therapy platforms and clinical-manufacturing tools at pan-European scale (CliniMACS, autoMACS). Thermo Fisher Supply Vilnius is the regional Baltic anchor for cell and gene therapy reagent inputs + bioprocessing CTS supply. The Viral Vector CDMO Europe 2026 brief covers the CDMO layer in depth.
Analysis
Regulation and ATMP pathway in 2026
Advanced Therapy Medicinal Products (ATMPs) are regulated under Regulation (EC) No 1394/2007 with centralised EMA approval via the Committee for Advanced Therapies (CAT). Every commercial CGT product in the EU routes through this pathway. The EU Biotech Regulation 2026 brief covers the wider pharmaceutical reform context (centralised pricing, exclusivity, access, environmental risk). For AI-enabled CGT adjacent systems (e.g. manufacturing control systems, clinical-decision support), the AI Act applies concurrently — Article 6(1) high-risk obligations for AI embedded in MDR/IVDR devices apply from August 2027. GMP compliance for ATMP manufacturing remains the primary operational constraint, and the European CDMO layer the directory covers is sized specifically for ATMP-scale regulatory work.
Analysis
How to pick a European CGT partner in 2026
Match the decision to the modality. CAR-T + TCR-T + CAR-NK: T-Knife, Anocca, Elicera, Zelluna, Antion Biosciences, Cimeio. Stem cell + regenerative ATMP: RHEACELL, Xintela, StemSight, Verigraft, ClexBio. Tissue-engineering biomaterials: PrintyMed, Vital3D, SCRC Vilnius, Verigraft. Tolerance-based therapy: PolTREG, TolerogenixX. Veterinary: Bioceltix. Viral-vector CDMO: FinVector, Kuopio Center for Gene and Cell Therapy, 3PBIOVIAN, IDT Biologika (plus platform-stage Fuse Vectors). Tools + clinical manufacturing: Miltenyi Biotec, Thermo Fisher Supply Vilnius. The Viral Vector CDMO Europe 2026 brief covers the manufacturing decision; the How to Pick a European Biotech Partner 2026 brief covers broader partner selection.
What to watch
What to watch next
T-Knife, Anocca, Elicera CAR-T / TCR-T pipeline progression through clinical milestones
PolTREG and TolerogenixX tolerance-based therapy clinical readouts
European viral-vector CDMO capacity expansion — FinVector, Kuopio Center, 3PBIOVIAN
Fuse Vectors cell-free AAV process-maturity milestones
RHEACELL, Xintela, StemSight stem-cell and regenerative-medicine clinical progression
EU Biotech Act implementation effect on ATMP manufacturing investment
FAQ
Frequently asked questions
Who runs European CAR-T and TCR-T cell therapy programmes?
The directory surfaces six operators at clinical stage: T-Knife (Berlin, TCR-T for solid tumors), Anocca (Södertälje, TCR-T with in-house manufacturing), Elicera Therapeutics (Gothenburg, CAR-T + oncolytic viruses), Zelluna ASA (Oslo, off-the-shelf TCR-NK), Antion Biosciences (Geneva, allogeneic CAR-T + multiplex gene silencing), Cimeio Therapeutics (Basel, shielded-cell therapy for hematologic disorders). For partnerships, these are the primary directory entries.
Where can I manufacture cell or gene therapy viral vectors in Europe?
Five European CDMO operators the directory surfaces: FinVector (Kuopio, Finland, clinical-to-commercial AAV + adenoviral); Kuopio Center for Gene and Cell Therapy (AAV + adenovirus + lentivirus CDMO); 3PBIOVIAN (Turku, biologics + viral vectors + pDNA); IDT Biologika (Dessau-Rosslau, Germany, viral vector + vaccine + fill-finish at commercial scale); Fuse Vectors (Copenhagen, pre-GMP platform-stage cell-free AAV). The Viral Vector CDMO Europe 2026 brief covers the full decision rule.
What European stem cell and regenerative medicine companies should I know?
RHEACELL (Heidelberg, stromal-cell therapy), Xintela (Lund, stem cell + ATMP), StemSight (Tampere, iPSC-derived corneal cell therapy), Verigraft (Gothenburg, tissue-engineered vascular grafts), ClexBio (Oslo, hydrogel scaffolds), PrintyMed (Latvia, spider-silk biomaterial scaffolds), Vital3D (Vilnius, 3D bioprinting), Stem Cell Research Center Vilnius, Froceth (Vilnius, adipose-derived cell therapy). Nine operators across Germany, Sweden, Finland, Norway, and the Baltics.
Is Miltenyi Biotec a CDMO or a tools company?
Miltenyi Biotec (Bergisch Gladbach, Germany) is classified in the directory as a tools operator — it makes cell-therapy platforms (CliniMACS, autoMACS) and clinical manufacturing tools used by CGT developers and CDMOs. It is not a contract manufacturer in the strict sense, though its systems are central to most European CGT clinical manufacturing workflows. For CDMO contracting, the directory points to operators like Kuopio Center for Gene and Cell Therapy, FinVector, or IDT Biologika.
How does the EU regulate ATMPs in 2026?
Advanced Therapy Medicinal Products (ATMPs) are governed under Regulation (EC) No 1394/2007 with centralised EMA approval via the Committee for Advanced Therapies (CAT). Cell therapies, gene therapies, tissue-engineered products, and combined products all fall under the ATMP regime. GMP compliance is mandatory for commercial manufacturing; clinical-trial authorisation runs through CTIS under the Clinical Trials Regulation. For AI systems embedded in CGT manufacturing or clinical workflows, AI Act Article 6(1) high-risk obligations apply from August 2027. See the EU Biotech Regulation 2026 brief for the full regulatory context.
Methodology note
Sources and interpretation
Sources: verified Memel Biotech directory entries for every CGT-adjacent operator, official company capability pages, EU ATMP + CTIS regulatory materials, and editorial comparison against the Viral Vector CDMO Europe 2026 and European mRNA & Immunotherapy 2026 briefs. The directory entry for each operator links to the authoritative company sources.
Disclaimer
Use limits
This brief is an editorial map of visible European cell and gene therapy activity in 2026. It does not rank operators, certify any specific regulatory or manufacturing status beyond public disclosures, or disclose non-public capacity — sponsors should verify directly with each operator before engagement.
Primary sources
Source list
Related pages
Related directory records
Briefs
Continue through related topics.
A useful brief should help people move into related records, cities, categories, and methodology pages without falling back into generic template language.